Investor Abdalkader Reports 6.22% Passive Stake in CorMedix

Rhea-AI Filing Summary

On 8 Aug 2025, individual investor Shaibatalhamd Aymen Abdalkader filed Amendment No. 2 to Schedule 13G, revealing a passive ownership position in CorMedix Inc. (CRMD).

• Shares owned: 4,645,630 common shares.
• Ownership percentage: 6.22 % of CorMedix’s outstanding stock, exceeding the 5 % disclosure threshold.
• Control rights: Sole voting and sole dispositive power over all reported shares; no shared control.
• Intent: Filer certifies the stake is not intended to influence or change control of the issuer.

No purchase prices, transaction dates, or financing details were disclosed. While the filing signals meaningful individual interest in CRMD, it conveys a passive stance and does not, by itself, indicate imminent strategic or governance changes.

Positive

• 6.22 % passive stake signals increased investor confidence from a new significant shareholder.

Negative

• Concentrated ownership in a single individual could create an overhang risk if the holder decides to exit.

Insights

Securities Analyst

TL;DR – 6.22 % passive stake disclosed; limited direct impact on CRMD fundamentals.

The filing shows Abdalkader now holds a material but non-activist position in CorMedix. A single holder above 5 % can add trading liquidity and may reflect confidence in the company’s prospects, yet the passive 13G certification limits expectations of strategic agitation. With no price or timing data, we cannot gauge cost basis or profit intent. Overall market impact is modest unless the investor’s future actions change.

Corporate Governance Expert

TL;DR – New significant shareholder, but passive filing indicates no control ambitions.

A 6 % holding gives visibility but little governance leverage without further coordination. The absence of group status and the 13G (rather than 13D) filing suggest compliance with a purely investment-oriented posture. Board composition and voting dynamics remain unaffected unless the investor later re-files under 13D or joins an activist consortium.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

CorMedix Inc.

(Name of Issuer)

COMMON STOCK, PAR V ALUE $0.001 PER SHARE

(Title of Class of Securities)

21900C308

(CUSIP Number)

08/08/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 21900C308

1

Names of Reporting Persons

SHAIBATALHAMD AYMEN ABDALKADER

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

SAUDI ARABIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,645,630.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 4,645,630.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

4,645,630.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6.2 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: CorMedix Inc.
(b)	Address of issuer's principal executive offices: 300 CONNELL DRIVE, SUITE 4200, BERKELEY HEIGHTS, NEW JERSEY, 07922
Item 2.
(a)	Name of person filing: SHAIBATALHAMD AYMEN ABDALKADER
(b)	Address or principal business office or, if none, residence: 7852, Al Batinah, 2650, Al Woroud Dist., Riyadh 12253, Saudi Arabia
(c)	Citizenship: Saudi Arabia
(d)	Title of class of securities: COMMON STOCK, PAR V ALUE $0.001 PER SHARE
(e)	CUSIP No.: 21900C308
Item 4.	Ownership
(a)	Amount beneficially owned: 4,645,630
(b)	Percent of class: 6.22 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 4,645,630
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 4,645,630
	(iv) Shared power to dispose or to direct the disposition of: 0

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

SHAIBATALHAMD AYMEN ABDALKADER

Signature:	SHAIBATALHAMD AYMEN ABDALKADER
Name/Title:	Individual
Date:	08/08/2025

FAQ

How many CorMedix (CRMD) shares were disclosed in the Schedule 13G/A?

The filing reports 4,645,630 common shares owned by Shaibatalhamd Aymen Abdalkader.

What percentage of CorMedix’s outstanding stock does the filing represent?

The stake equals 6.22 % of CRMD’s shares outstanding.

Is the investor pursuing an activist strategy in CRMD?

No. The Schedule 13G certification states the shares are held without intent to influence control of the issuer.

Does the investor have shared voting or dispositive power over the shares?

No. The filing lists sole voting and dispositive power over all reported shares.

What is the CUSIP number for CorMedix common stock?

The CUSIP identified in the filing is 21900C308.